Drug news
NICE recommends Tasigna (Novartis) for CML
In final draft guidance, NICE has recommended Tasigna (nilotinib), from Novartis, for CML. The decision is not based on direct data. The independent appraisal committee concluded from indirect comparisons that the drug is effective in treating CML. The panel found that the most plausible Incremental Cost-effectiveness Ratio (ICER) for Tasigna compared with standard-dose Glivec was considered to be �11,000 per Quality-Adjusted Life Year (QALY) gained.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.